3505 Background: Doublets plus bev are a standard option for the first-line treatment of
mCRC. First-line FOLFOXIRI demonstrated superior RR, PFS and OS compared to FOLFIRI. A …

Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC)
patients with unresectable liver-limited disease. Medical treatment has a dual goal: to …

3505 Background: Since doublets plus anti-EGFRs were continued until progressive
disease (PD) in mCRC first-line registration trials, there is scarce evidence if de-escalating …

Background Oligometastatic disease (OMD) identifies tumours with limited metastatic spread.
OMD definition is not univocal and no data from clinical trials are available about the …

336 Background: First-line FOLFOXIRI demonstrated superior activity and efficacy compared
to FOLFIRI. Moreover, the outcome is improved by the addition of bev to first-line doublets. …

Background A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a
monoclonal antibody against vascular endothelial growth factor), is standard first-line …

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients with …

Importance Primary tumor location is emerging as an important prognostic factor owing to
distinct biological features. However, the side of origin of colon cancer (CC) still does not …

Importance Obesity, defined as a body mass index (BMI) greater than 30, is associated with
a significant increase in the risk of many cancers and in overall mortality. However, various …

Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, …